Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study
- 26 April 2014
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 89 (7) , 751-756
Abstract
The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However, the differences in clinical characteristics between ethnic groups are not well‐defined. In Asian countries, although the incidence of MM has been lower than that of Western countries, there is growing evidence that MM is increasing rapidly. The Asian Myeloma Network decided to initiate the first multinational project to describe the clinical characteristics of MM and the clinical practices in Asia. Data were retrospectively collected from 23 centers in 7 countries and regions. The clinical characteristics at diagnosis, survival rates and initial treatment of 3,405 symptomatic MM patients were described. Median age was 62 years (range, 19–106), with 55.6% of being male. Median overall survival (OS) was 47 months (95% CI 44.0–50.0). Stem cell transplantation was performed in 666 patients who showed better survival rates (79 vs. 41 months, P < 0.001). The first‐line treatments of 2,970 patients were analyzed. The overall response rate was 71% including very good partial response or better in 31% of the 2,660 patients those were able to be evaluated. New drugs including bortezomib, thalidomide, and lenalidomide were used in 36% of 2,970 patients and affected OS when used as a first‐line treatment. Am. J. Hematol. 89:751–756, 2014.Keywords
This publication has 24 references indexed in Scilit:
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working PartyInternational Journal of Hematology, 2010
- Comparison Among Immunologically Different Subtypes of 595 Untreated Multiple Myeloma Patients in Northern ChinaClinical Lymphoma Myeloma and Leukemia, 2010
- Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma RegistryActa Haematologica, 2009
- Epidemiology of multiple myeloma in TaiwanCancer, 2007
- Lung Injury Associated with Bortezomib Therapy in Relapsed/Refractory Multiple Myeloma in Japan: A Questionnaire-Based Report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical HematologyInternational Journal of Hematology, 2006
- Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myelomaCancer Genetics and Cytogenetics, 2006
- Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myelomaBlood, 2006
- Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in TaiwanAnnals of Oncology, 2005
- Ten‐year survival and prognostic factors in multiple myelomaBritish Journal of Haematology, 1994